Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and their stock prices) often stay small because their subscale operations make it harder to expand their competitive moats.

Luckily for you, our mission at StockStory is to help you make money and avoid losses by sorting the winners from the losers. That said, here is one small-cap stock that could be the next big thing and two that may have trouble.

Two Small-Cap Stocks to Sell:

Integra LifeSciences (IART)

Market Cap: $731.1 million

Founded in 1989 as a pioneer in regenerative medicine technology, Integra LifeSciences (NASDAQ: IART) develops and manufactures medical technologies for neurosurgery, wound care, and surgical reconstruction, including regenerative tissue products and surgical instruments.

Why Do We Steer Clear of IART?

1. Absence of organic revenue growth over the past two years suggests it may have to lean into acquisitions to drive its expansion
2. Free cash flow margin dropped by 19 percentage points over the last five years, implying the company became more capital intensive as competition picked up
3. High net-debt-to-EBITDA ratio of 6× could force the company to raise capital at unfavorable terms if market conditions deteriorate

At $9.38 per share, Integra LifeSciences trades at 4.1x forward P/E. To fully understand why you should be careful with IART, check out our full research report (it’s free).

Robert Half (RHI)

Market Cap: $2.49 billion

With roots dating back to 1948 as the first specialized recruiting firm for accounting and finance professionals, Robert Half (NYSE: RHI) provides specialized talent solutions and business consulting services, connecting skilled professionals with companies across various fields.

Why Are We Out on RHI?

1. Products and services are facing significant end-market challenges during this cycle as sales have declined by 8.3% annually over the last two years
2. Performance over the past five years shows its incremental sales were much less profitable, as its earnings per share fell by 13.3% annually
3. Diminishing returns on capital suggest its earlier profit pools are drying up

Robert Half’s stock price of $25.10 implies a valuation ratio of 16.7x forward P/E. If you’re considering RHI for your portfolio, see our FREE research report to learn more.

One Small-Cap Stock to Watch:

First BanCorp (FBP)

Market Cap: $3.26 billion

Tracing its roots back to 1948 in San Juan, First BanCorp (NYSE: FBP) is a bank holding company that provides commercial banking, consumer financing, mortgage services, and insurance products across Puerto Rico, the U.S. mainland, and the Caribbean.

Why Are We Positive On FBP?

1. Share buybacks catapulted its annual earnings per share growth to 37.3%, which outperformed its revenue gains over the last five years
2. Annual tangible book value per share growth of 20.1% over the last two years was superb and indicates its capital strength increased during this cycle

First BanCorp is trading at $21.29 per share, or 1.5x forward P/B. Is now the right time to buy? See for yourself in our comprehensive research report, it’s free.

High-Quality Stocks for All Market Conditions

WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don't just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.

But our AI platform says the party isn't over. Find out which 9 stocks made the cut this week — FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.